US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Lorazepam Injection

Reason Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

Hikma Pharmaceuticals USA Inc. NDC 0641-6044-25 D-0551-2025
Class II · Moderate risk Ongoing

Quick Touch Alcohol Prep Pads

Reason cGMP Deviations

Yangzhou Yulou Paper Products CO., LTD D-0659-2025
Class II · Moderate risk Ongoing

Belsomra

Reason Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.

Merck & Co. Inc NDC 0006-0033-10 D-0584-2025
Class I · High risk Ongoing

PeriGiene

Reason Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.

DermaRite Industries, LLC NDC 61924-198-08 D-0613-2025
Class I · High risk Ongoing

KleenFoam

Reason Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.

DermaRite Industries, LLC NDC 61924-093-34 D-0612-2025
Class I · High risk Ongoing

DermaSarra

Reason Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.

DermaRite Industries, LLC NDC 61924-189-08 D-0611-2025
Class I · High risk Ongoing

DermaKleen

Reason Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.

DermaRite Industries, LLC NDC 61924-092-27 D-0610-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit

Breckenridge Pharmaceutical, Inc. NDC 51991-748-10 D-0552-2025
Class II · Moderate risk Ongoing

Sucralfate Tablets

Reason CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Nostrum Laboratories, Inc. NDC 29033-0003-01 D-0547-2025